Phantom Neuro Showcases Minimally Invasive Neural Interface Strategy

A LinkedIn post from Phantom Neuro highlights an interview on the Core Memory show featuring Founder and CEO Connor Glass discussing the company’s Phantom X system. According to the post, Phantom X aims to enable control of external devices by capturing electrical signals from the body rather than using brain-computer interfaces that require brain surgery.

The post suggests the implant is placed subcutaneously in the limb, where signals are described as easier to detect and decode, particularly for individuals with limb loss whose upstream neural pathways remain intact. By focusing on what are characterized as larger, more stable signals, the approach is presented as supporting a more scalable human–machine interface across multiple applications, including neurotechnology, medtech, and defense-related use cases.

For investors, this emphasis on minimally invasive signal capture could indicate a strategy to lower clinical risk and broaden patient eligibility compared to invasive brain implants, potentially improving adoption prospects and time-to-market. The referenced applications across medical rehabilitation and defense innovation may imply a diversified revenue opportunity if the technology proves clinically effective, is reimbursed by payers where relevant, and secures procurement interest from government or defense customers.

The media appearance also points to an effort to raise Phantom Neuro’s visibility among technology and healthcare stakeholders, which can be important for future fundraising and partnership development. However, the post does not provide data on regulatory status, clinical outcomes, pricing, or commercialization timelines, leaving material uncertainty around the pace and scale of potential revenue generation.